Protocol Ledger

NCT05660954 · Phase II · COMPLETED

Cabozantinib In Advanced Radioactive-Iodine Refractory Differentiated Thyroid Cancer.

Interventional Phase II clinical trial protocol NCT05660954 sponsored by Grupo Espanol de Tumores Neuroendocrinos in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2023-05-25 Enrollment: 41 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT05660954
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)41 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT05660954
Protocol FieldVerified Registry Value
NCT IdentifierNCT05660954
Consolidated Lead SponsorGrupo Espanol de Tumores Neuroendocrinos
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase II
Overall Recruitment StatusCOMPLETED
Registered Enrollment41 participants (ACTUAL)
Registered Start Date2023-05-25
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT05660954
Hospital Research SiteLocationSite Profile
Hospital Universitario Vall d'HebronBarcelona, SpainOpen Hospital Dossier ->
Hospital Clínic de BarcelonaBarcelona, SpainOpen Hospital Dossier ->
Hospital Universitario Ramón y CajalMadrid, SpainOpen Hospital Dossier ->
Hospital Clínico San CarlosMadrid, SpainOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI